Summary The oxy-radical scavenger enzyme manganese superoxide dismutase (MnSOD) may act in the capacity of a tumour-suppressor gene. To address the issue of its role in tumour transformation and progression in vivo, we evaluated the content of this enzyme in 33 brain tumours of neuroepithelial origin with different degrees of differentiation (WHO grade II-IV) by means of Western blot and immunohistology. Our results show that immunoreactive MnSOD increases in a direct relationship with tumour grade and is therefore inversely correlated with differentiation. The increase is induced at a pretranscriptional level and is apparently specific to brain tumours of neuroepithelial origin. Approximately 30% of grade IV tumours display low levels of MnSOD content, and preoperative radiotherapy and brachytherapy result in low amounts of enzyme. Based upon these observations, we suggest that MnSOD cannot be considered a classical tumour-suppressor gene.
The mitochondrial scavenger enzyme manganese superoxide dismutase (MnSOD) is one of the three SODs that catalyse the dismutation of superoxide radicals to oxygen and hydrogen peroxide in eukaryotes, the other two being cytosolic CuZnSOD and extracellular CuZnSOD. While cytosolic CuZnSOD is a constitutive enzyme, MnSOD is an inducible protein, and the expression of its gene is regulated by the redox state of the cell and by cytokines, among which a dominant role is played by IL-1 and TNF-oa (Hassan, 1988; Harris, 1992; Wong, 1995) .
In experimental rat hepatocarcinomas, the MnSOD content decreases following an inverse relationship with the degree of differentiation (Galeotti et al., 1989) . A decrease in MnSOD content has also been reported in human neoplastic pathology, both in in vitro cell lines and in in vivo tumours (Sun, 1990) . Furthermore, the steps of human hepatocarcinogenesis are accompanied by a progressive decrease of both CuZnSOD and MnSOD. According to these observations, a reduction in MnSOD has been looked at as a key point for malignant transformation and/or tumour progression, and it has been suggested that MnSOD could behave as a tumoursuppressor protein by preventing oxy-radical-mediated DNA damage (Sun, 1990; Bravard et al., 1992a, b; Church et al., 1993; Li et al., 1995) .
In contrast with this hypothesis, conflicting results have been reported for lung cancers (lizuka et al., 1984) . Moreover, measurement of MnSOD by ELISA showed that its levels were increased in the sera of 12 out of 23 patients suffering from ovarian tumours (Ishikawa et al., 1990) and in 8 out of 12 patients suffering from neuroblastoma (Kawamura et al., 1992) .
Brain tumours of neuroepithelial origin are classified on the basis of histological characteristics and of predominant cell type. Presence and degree of nuclear atypias, atypical mitosis, cell polymorphism, vascular proliferation and necrosis, together with the mitotic index, determine the histological grading. These tumours offer an interesting model for research, dealing with the processes of tumour initiation and progression. In most cases, the histological grade of malignancy is linked to their prognosis, as happens in experimental tumours. Better differentiated tumours often evolve into more malignant forms, demonstrating an example of progression of neoplastic disease. It has also been reported that TNF-a can be secreted by human glioblastoma cell lines, by some glioblastomas and by peritumoral brain tissue (Nitta et al., 1994) . Therefore, it was interesting to examine the role and regulation of MnSOD in the group of brain tumours of glial origin as they offer an in vivo model in which different degrees of differentiation, progression of disease and TNF-a secretion can be found.
A further point of interest in such a study is the fact that some low-grade tumours have an unexpectedly accelerated evolution towards high-grade, highly malignant tumours. One goal of current research in neurosurgery is to identify histological and/or biochemical parameters that may help in highlighting such a group within the good-prognosis, lowgrade group of malignancies. This type of marker would allow identification of patients with less favourable prognosis who would benefit from more aggressive treatment. Several biological markers have been studied in this respect. Some of these markers are related to growth rate and cell cycle, such as labelling index (Franzini et al., 1994) , PCNA (Korkolopoulou et al., 1993 ), BrdU (Labrousse et al., 1991 and Ki-67 (Morimura et al., 1991) . Others refer more directly to tumour biology, such as amplification of the EGF receptor gene (Hurtt et al., 1992; Schlegel et al., 1994) , loss of heterozygosity (LOH) for p53 (Fults et al., 1992; von Deimling et al., 1992; Rasheed et al., 1994) , LOH for chromosome 19q (Ritland et al., 1995) and annexin II expression (Roseman et al., 1994) . However, the field is still open to further contributions as no marker has yet proved to be an effective identifier. Therefore, it would also make sense to evaluate in a preliminary way whether the MnSOD can be studied as a metabolic marker of progression. If so, it might be used in a study dedicated to prove its effectiveness in identifying the group of low-grade tumours that are at a higher risk of accelerated progression of the disease.
The main goal of the experiments that we report in the present paper was to further our knowledge on the role of MnSOD in tumour transformation and progression in an in vivo human model. We asked whether variation of MnSOD can be observed in tumours of glial origin with respect to normal controls, and if these variations are linked to the degree of differentiation and, if so, which molecular mechanism is responsible for them.
In order to address these issues, we analysed 38 brain tumours, 33 of neuroepithelial origin and five of extraneural origin. We assessed the amount of the MnSOD protein in the neoplastic tissues and evaluated the expression of its mRNA. These results were subsequently compared with the histological grade. Materials and methods
Patients
Between May 1994 and October 1995, specimens from 33 brain tumours of neuroglial origin were collected (see Table  I ). Glioblasto-ma no. l18 (++) MW standard 1879 1 monomeric MnSOD (26 kDa apparent molecular weight). As a positive control, a sample immunoprecipitated from human normal liver was also run. This gave a reproducible intensity of the band corresponding to MnSOD. To exclude intersample variations, most samples were run at least twice.
RNA isolation RNA was isolated as according to Chomezynski et al. (1987) by RNAs extraction and purification solution (Bioprobe Table I . In order to have further information and to be able to study smaller samples such as biopsies, we also used the same antibody for immunohistological studies, using both fluorescent and peroxidase conjugated detection systems. The results are listed in Table II and are shown in Figures 1 and 2 . Figure 1 shows the WB analysis of some representative tumours; the arrows indicate the band corresponding to monomeric MnSOD. In some of the tumours reported in Figure 1 , two extra bands can be seen; the one slower than monomeric MnSOD represents the cytosolic precursor of the protein (Ria et al., 1993; Kawaguchi et al., 1989) , while the faster one represents products of the degradation occurring in vivo (ME De Leo, manuscript in preparation). As described in the Materials and methods section, the amount of MnSOD was evaluated according to the intensity of the band corresponding to monomeric MnSOD. In order to assess the information obtained using the two different techniques, we compared the results obtained using WB and IH in 22 patients that were independently evaluated with both methods. Results are shown in Figure 3 and describe the correlation of the values observed. As expected, there is a highly significant (P=0.001) correspondence of the values estimated with these approaches in all of the types of tumour (Pearson's rho coefficient = 0.6369, n = 22, df= 6), with the only exception of two glioblastomas that display a remarkable difference in the amount of protein detected by WB (4+) compared with that detected by IH (0-+).
The MnSOD content was evaluated with respect to tumour grading. When both WB and IH data were available, the highest value was used. Results are shown in Figure 4 and demonstrate a significant correlation between tumour grading and MnSOD content P = 0.005, chi-square = 18.80, df=6 Preoperative RT and brachytherapy may account for the low amount of detectable MnSOD as found in some tumours. In fact two patients (one grade III and one grade IV) were evaluated as belonging to class 1, and three (1 grade III and 2 grade IV) as belonging to class 2. In these samples, we observed a low number of cells, not always clearly neoplastic, with large areas of necrosis. However, even if these patients are not considered, it is evident that there is a consistent group of grade IV tumours (4/13 30%) showing low levels of MnSOD.
We measured the activity of the enzyme in tumours nos. 2, 3 (grade II), 11 (grade III), 18, 19, 20, 21 (grade IV) (not shown). Even in those tumours that displayed very high levels of immunoreactive protein, no increase of the enzymatic activity was found with respect to normal brain or grade II tumours (see Discussion).
We then monitored the quantity of mRNA specific for MnSOD, using Northern blot. The results (reported in Table   4 III and Figure 5) show a tight correlation between mRNA and protein content and suggest that the increase of MnSOD content is due to higher levels of specific mRNA. We also evaluated the content of MnSOD in five brain tumours of extraglial origin, and the results are shown in Figure 6 . Four out of the five neoplasias tested (one NHL, one haemangiopericytoma and two metastases from different lung adenocarcinomas) showed low levels of MnSOD both in WB and IH, while 1 metastasis from colon adenocarcinoma showed a + + + amount of MnSOD in WB and a -level in IH.
As patient no. 26 suffered a malignant relapse of an anaplastic astrocytoma, and patient no. 33 died within 30 days after surgery, we report in Table IV the survival of 14 out of 16 patients suffering from glioblastoma. The subjects are listed according to the amount of MnSOD, together with their Karnowski performance index, diameter, residual disease and surviving time. 
Discussion
The aim of our experiments was to address some questions about the role of MnSOD in tumour transformation and progression: can we describe variations in the scavenger enzyme MnSOD content that depend on the tumour grade of anaplasia in human in vivo models?; which mechanisms sustain these variations?; is it possible that MnSOD behaves as a tumour-suppressor protein?
To approach these problems, we chose brain tumours of neuroepithelial origin as a model in which we could find various degrees of histological, biological and clinical differentiation, progression of disease and secretion of the cytokines involved in the regulation of the gene encoding for MnSOD.
We previously reported that MnSOD content follows an inverse relationship with the tumour malignancy in experimental rat hepatocarcinomas (Galeotti et al., 1989) , and other authors reported a tight link between MnSOD decrease and the processes of tumour transformation and progression in several human models, both in vitro and in vivo (Sun, 1990) . We previously reported that a metastasis from an adenocarcinoma of the colon was negative for MnSOD within a strongly positive normal liver tissue (Ria et al., 1994) and in the present report we show that four out of five nonglial brain tumours also display very low levels of the enzyme under study. Thus, all these results would support a general view that MnSOD has somehow to decrease during tumour transformation or progression (Sun, 1990) . The most noteworthy exceptions reported so far have been the increases of MnSOD levels in the sera of approximately 50% of the patients affected by ovarian cancer and neuroblastoma (Ishikawa et al., 1990; Kawamura et al., 1992) . These observations may also be explained by a high death rate in tumour tissues, rather than by increased MnSOD content alone. In fact, immunocytochemical detection was performed only sporadically, and in the same reports it was observed that chemotherapy of neuroblastomas increases these levels (Kawamura et al., 1992) .
The data that we report in the present paper, attest that MnSOD, when studied in brain tumours of neuroepithelial origin, exhibits a behaviour opposite to that expected. In fact, our findings indicate that the cellular content of immunoreactive MnSOD increases in tandem with histological grading, i.e. it is in a direct relationship with loss of differentiation and with biological and clinical malignancy. We can therefore rule out the hypothesis that the gene encoding for MnSOD is a tumour-suppressor gene according to the classical definition. However, the reasons for this inverse comportment remain to be explained. We suggest two hypotheses that may reconcile this model with the others.
The first hypothesis stems from the observation that the enzyme activity does not increase proportionally with the immunoreactive protein. A similar lack of correlation between enzyme activity and immunoreactive protein was also reported for lung adenocarcinomas (lizuka et al., 1984) .
The difference between protein and enzymatic activity may be dependent on the lack of metal co-factor; it has been reported that manganese content decreases in a number of tumours, compared with their tissue of origin (Ling et al., 1990) . We also observed an increase of efflux of manganese in experimental models of hepatocarcinoma, resulting in decreased content of metal (Galeotti et al., 1995) . Thus, the possibility remains that a decrease of dismutase activity in the cells occurs during tumour transformation as a consequence of various mechanisms, independently from the fate of immunoreactive protein.
The second hypothesis originates from the fact that the increase of immunoreactive protein is linked to the rise of specific mRNA. As described above, both the redox state of the cell itself and cytokines (mainly IL-1 and TNF-cx) are involved in the regulation of the gene encoding for the MnSOD (Hassan, 1988; Harris, 1992; Wong, 1995) , and autocrine and/or paracrine secretion of these cytokines by glioblastomas or by the brain tissue surrounding the tumour was reported (Nitta et al., 1994) . Immunoreactive MnSOD We observed low levels of immunoreactive MnSOD in some ( 30%) of the glioblastomas that we studied. The histological examination of adjacent slices excluded that this finding was associated with necrotic or more differentiated areas which are frequently present in multiform glioblastomas. Biological and metabolic characteristics of those glioblastomas that show this discrepancy will need to be clarified in further research.
As mentioned in the introduction, a major problem that neurosurgeons face is the attempt to highlight a population of low-grade tumours that follow an accelerated clinical course. The number of cases and the length of observation period did not allow us to address this issue directly in grade II or III tumours. However, our preliminary observations convey the impression that 'lower' levels of MnSOD may be related to longer survival within the group of patients suffering from glioblastomas, although the data cannot be processed by means of statistical analysis.
Thus, three observations support the proposal of a larger study that will use the MnSOD content as a metabolic marker of progression: (1) MnSOD increases with tumour grading; (2) a very small number of grade II tumours (1/10) display high levels of immunoreactive protein, in accordance with the fact that only a few low-grade tumours have an accelerated progression; (3) within a histologically defined group, higher levels of MnSOD suggest a more elevated aggressiveness of the disease.
